**Core Concept:** Chronic myeloid leukemia (CML) is a type of cancer that affects the blood-forming cells in the bone marrow. In chronic phase, the main focus of treatment is to control the disease progression and improve the patient's quality of life.

**Why the Correct Answer is Right:** The correct answer, imatinib (Gleevec), is a tyrosine kinase inhibitor (TKI) that is highly effective in treating chronic phase CML. Imatinib targets the BCR-ABL1 fusion gene, which is the underlying genetic abnormality responsible for the disease. By inhibiting the abnormal BCR-ABL1 protein, imatinib prevents uncontrolled cell growth and differentiation of myeloid cells, resulting in the suppression of the disease progression.

**Why Each Wrong Option is Incorrect:**

A. Imatinib is a first-line treatment for chronic phase CML, making this option incorrect.
B. Hydroxyurea is an antineoplastic agent but is not specifically targeted at the BCR-ABL1 fusion gene, so this option is not suitable for treating chronic phase CML.
C. Pegylated interferon-alpha is an interferon used for treating viral infections and autoimmune diseases, not specifically targeting BCR-ABL1 fusion gene, making this option incorrect.
D. Busulfan is an alkylating agent used for treating various cancers but lacks the specificity for the BCR-ABL1 fusion gene, so this option is not the best choice for treating chronic phase CML.

**Clinical Pearl:** Imatinib is a crucial drug in the management of chronic phase CML. It is the cornerstone of treatment, improving survival rates, and quality of life for patients. Understanding the molecular basis of the disease and the mode of action of imatinib is essential for treating this condition effectively.